Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you use bolus in patients s/p mastectomy and reconstruction if they had dermal involvement?
Answer from: Radiation Oncologist at Community Practice
Pathological dermis involvement is a risk factor of LR and I would use bolus for this situation.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
While we are increasingly omitting bolus, dermal involvement would concern me and I would use bolus.
Comments
Radiation Oncologist at University of Miami/Jackson Memorial Medical Center
Drs. @Sushil Beriwal and @Chirag S. Shah, would yo...
Radiation Oncologist at Allegheny Health Network, Pittsburgh
I typically start with 1st 13 fractions and will m...
Radiation Oncologist at Indiana University Health
@Sushil Beriwal @Chirag S. Shah Would you consider...
9600
9602
15122
Sign in or Register to read more
11755
11772
Related Questions
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
Do you consider chest wall constraints when treating with 5-fraction APBI?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you recommend PMRT to a clinically node positive (biopsy proven axillary node and indeterminate single IMN node) BRCA positive patient with multiple medical co-morbidities including scleroderma and ILD who is treated with neoadjuvant chemotherapy (NAC) and mastectomy who converts to ypT0/ypN0?
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
What is the earliest you would start postmastectomy radiation after adjuvant chemotherapy for a patient with breast cancer?